| Bioactivity | Cofirasersen is designed to reduce the expression of ENaC in the lung. ENaC is a sodium transport channel and believed to be hyperactive in cystic fibrosis, which is caused by mutations in the cystic fibrosis transmembrane regulator gene. |
| Name | Cofirasersen |
| CAS | 2247669-96-9 |
| Formula | C172H218N57O88P15S15 |
| Molar Mass | 5437.55 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. WHO Drug Information, Vol. 34, No. 3, 2020 |
Cofirasersen
CAS: 2247669-96-9 F: C172H218N57O88P15S15 W: 5437.55
Cofirasersen is designed to reduce the expression of ENaC in the lung. ENaC is a sodium transport channel and believed t
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.